Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 3.63 GBp
Change Today 0.00 / 0.00%
Volume 424.0K
As of 7:59 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

reneuron group plc (RENE) Snapshot

3.63 GBp
Previous Close
3.63 GBp
Day High
3.63 GBp
Day Low
3.63 GBp
52 Week High
12/2/14 - 4.39 GBp
52 Week Low
06/16/14 - 2.75 GBp
Market Cap
Average Volume 10 Days
-0.0040 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for RENEURON GROUP PLC (RENE)

Related News

No related news articles were found.

reneuron group plc (RENE) Related Businessweek News

No Related Businessweek News Found

reneuron group plc (RENE) Details

ReNeuron Group plc is engaged in the research and development of stem cell technologies for therapeutic and non-therapeutic applications worldwide. Its lead therapeutic candidate is ReN001 stem cell therapy, which is in Phase II clinical trial for the treatment of patients left disabled by the effects of a stroke. The company is also developing ReN009 stem cell therapy candidate that is in Phase I clinical trial to treat critical limb ischaemia; and ReN003 stem cell therapy candidate, which is in pre-clinical trial for the treatment of retinitis pigmentosa. In addition, it develops and markets a range of stem cell lines, including ReNcell VM, a neural cell line derived from the ventral mesencephalon region of the brain; and ReNcell CX that is derived from the cerebral cortex. ReNeuron Group plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

27 Employees
Last Reported Date: 07/12/14
Founded in 1997

reneuron group plc (RENE) Top Compensated Officers

Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: 228.0K GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 262.0K GBP
Compensation as of Fiscal Year 2014.

reneuron group plc (RENE) Key Developments

ReNeuron Group plc Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 02:10 PM

ReNeuron Group plc Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 02:10 PM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: Michael E. Hunt, Chief Financial Officer and Executive Director.

ReNeuron Group plc Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

ReNeuron Group plc Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

ReNeuron Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2014

ReNeuron Group plc reported unaudited consolidated earnings results for the six months ended September 30, 2014. For the period, the company reported revenue of GBP 11,000 against GBP 11,000 a year ago. Operating loss was GBP 4,907,000 against GBP 3,493,000 a year ago. Loss before income taxes was GBP 4,867,000 against GBP 3,478,000 a year ago. Total comprehensive loss attributable to equity owners of the company was GBP 4,128,000 against GBP 3,167,000 a year ago. Basic and diluted loss per share was 0.2 pence against 0.3 pence a year ago. Cash outflow from operating activities was GBP 4,834,000 against GBP 3,422,000 a year ago. Capital expenditure was GBP 22,000 against GBP 59,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RENE:LN 3.63 GBp 0.00

RENE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $5.05 USD +0.08
Geron Corp $3.73 USD +0.08
International Stem Cell Corp $0.06 USD +0.0004
Neuralstem Inc $2.02 USD -0.10
Ocata Therapeutics Inc $6.20 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation RENE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 81.0x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 80.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RENEURON GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at